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Poor understanding of the basic biology ofMycobac-
terium tuberculosis (MTB), the etiological agent of
tuberculosis, hampers development of much-needed
drugs, vaccines, and diagnostic tests. Better experi-
mental tools are needed to expedite investigations
of thispathogenat thesystems level.Here,wepresent
a functional MTB proteome microarray covering
most of the proteome and an ORFome library. We
demonstrate the broad applicability of the microarray
by investigating global protein-protein interactions,
small-molecule-proteinbinding, andserumbiomarker
discovery, identifying 59 PknG-interacting proteins,
30 bis-(30-50)-cyclic dimeric guanosine monophos-
phate (c-di-GMP) binding proteins, and 14 MTB
proteins that together differentiate between tubercu-
losis (TB) patients with active disease and recovered
individuals. Results suggest that the MTB rhamnose
pathway is likely regulated by both the serine/threo-
nine kinase PknG and c-di-GMP. This resource has
the potential to generate a greater understanding of
keybiological processes in the pathogenesis of tuber-
culosis, possibly leading to more effective therapies
for the treatment of this ancient disease.INTRODUCTION
Mycobacterium tuberculosis (MTB), the etiological agent of
tuberculosis and one of the most successful human pathogens,Cell Recaused 8.6 million incident cases of tuberculosis (TB) and
claimed 1.3 million lives in 2012 (WHO, 2013) in spite of cen-
tury-long efforts to combat it. More effective drugs, vaccines,
and diagnostic tests for TB are clearly needed, but their develop-
ment is hampered by poor understanding of the basic biology of
this pathogen (Galagan et al., 2013). Global studies on MTB at
the systems level rather than traditional one-gene or one-protein
approaches should lead to breakthroughs (Boshoff and Lun,
2010), but better tools with which to investigate the basic biology
of MTB and its interactions with the host at the systems level are
urgently needed (McFadden et al., 2013).
High-throughput ‘‘omics’’ techniques have been applied to the
study of MTB biology in recent years to address questions at the
systems level; genomic studies are increasing our understanding
of MTB evolution (Comas et al., 2013) and the development of
drug resistance (Farhat et al., 2013; Zhang et al., 2013), while
proteomic studies, which have identified 80% of all annotated
MTB proteins (Schubert et al., 2013), the protein constituents of
different cellular locations (Gu et al., 2003), and the in vivo MTB
proteome (Albrethsen et al., 2013), and metabolomic studies
are opening up our understanding of the real-time physiological
status of bacilli in the host (Shin et al., 2011).
Proteome microarrays, usually composed of thousands of
proteins from one species that are affinity purified and function-
ally active, are powerful highly parallel, high-throughput plat-
forms for globally profiling thousands of molecular interactions
in a single experiment (Chen et al., 2008; Zhu et al., 2001). Their
use in the discovery of serum biomarkers for various diseases
(Gnjatic et al., 2010) and global investigations of protein interac-
tions with other proteins (PPI) (Chen et al., 2013), with DNA (Lin
et al., 2009), with RNA (Zhu et al., 2007), with lipids (Lu et al.,
2012), and with a range of small molecules (Huang et al., 2004)
demonstrate the power of this approach. Furthermore, theyports 9, 2317–2329, December 24, 2014 ª2014 The Authors 2317
can also be used to study post-translational modifications
(PTMs), including phosphorylation (Newman et al., 2013), acety-
lation (Lin et al., 2009), glycosylation (Kung et al., 2009), and
nitrosylation (Lee et al., 2014), providing a window into dynamic
cellular responses to changes in the environment. To date, the
only MTB proteome-scale microarray available is one devel-
oped using an E. coli-based cell-free transcription/translation
system where translated proteins were printed directly onto
nitrocellulose-coated slides without further purification (Kun-
nath-Velayudhan et al., 2010). While representing a significant
breakthrough toward defining the TB immunoproteome by facil-
itating proteome-scale analysis of serum samples, proteins on
an array developed using this approach lack the purity necessary
for broader functional studies. Difficulties in developing a suit-
able system for high-throughput protein expression and purifica-
tion have, however, impeded the development of a functional
MTB proteome microarray, as MTB proteins expressed in the
E. coli system are frequently insoluble or trapped in inclusion
bodies (Liu et al., 2014).
Here, we present a functional MTB proteome microarray
developed using a yeast expression system and demonstrate
its broad utility by using it to investigate protein-protein interac-
tions and small-molecule-protein binding and identify serum
biomarkers. We show that PknG, a Ser/Thr kinase (Prisic et al.,
2010), and bis-(30-50)-cyclic dimeric guanosine monophosphate
(c-di-GMP), a ubiquitous bacterial second messenger (Ro¨mling
et al., 2013), are both involved in the regulation of the rhamnose
biosynthesis pathway, a key pathway in cell wall synthesis
(Brennan, 2003). In addition, we identified 14 serum biomarkers
that can together differentiate between TB patients with active
disease and recovered individuals and thus have potential as
an index for monitoring treatment outcome. Our findings demon-
strate the potential of the MTB proteome microarray for greatly
increasing our understanding of the basic biology of TB and
identifying additional molecular targets in the fight against this
disease.
RESULTS
Construction of the MTB Proteome Microarray
To develop a suitable system for protein expression and purifica-
tion, we first compared the expression of randomly selected
MTB proteins in an E. coli system (Studier and Moffatt, 1986)
with that in a Saccharomyces cerevisiae system that has previ-
ously been used to construct yeast (Zhu et al., 2001) and human
proteome microarrays (Jeong et al., 2012). Consistent with pre-
vious reports that MTB proteins are difficult to express in E. coli
(Liu et al., 2014), possibly due to the high GC content of MTB
genes and unusual codon usage, less than 50% of 94 randomly
selected proteins were expressed successfully in E. coli, and
only 8 of these proteins were soluble (data not shown). Although
a separate study showed that codon optimization significantly
increases soluble expression in E. coli (13 of 16 tested proteins
were solubly expressed at significantly higher levels after codon
optimization; data not shown), the cost of using a codon optimi-
zation and whole-gene synthesis strategy to construct a prote-
omemicroarray for MTB was considered prohibitive. Expressing
MTB proteins using the S. cerevisiae system was found to2318 Cell Reports 9, 2317–2329, December 24, 2014 ª2014 The Autprovide an attractive and cost-efficient alternative; 95 of 100
randomly selected proteins were successfully expressed in
soluble form (data not shown). We thus chose the S. cerevisiae
system to construct the MTB proteome microarray.
To express and purify MTB proteins for the microarray, we
first shuttled 3,841 open reading frames (ORFs) in Gateway
Entry vectors obtained from the Pathogen Functional Genomics
Research Center (PFGRC), along with 794 additional full-length
and sequence-verified ORFs generated in our lab, into a yeast
expression vector (pEGH-A) that allows galactose-dependent
overexpression of N-terminal glutathione S-transferase (GST)-
tagged recombinant proteins as previously described (Jeong
et al., 2012). The final expression library included 3,829
H37Rv clones and 433 CDC1551 clones (Figure 1A). After
high-throughput expression and purification, performed as
described previously (Jeong et al., 2012) with minor modifica-
tions (Figure S1), we determined the protein quality of a random
selection of recombinant proteins using GST immunoblotting
(249 proteins) (Figure 1B; Data S1) and capillary electrophoresis
(305 proteins) (Figure 1C; Data S2). Many of the GST-fused MTB
proteins (222/249) showed a clear band of the expected size
(±10 kDa) and good purity, indicating that 90% (222/249 =
89.28%) of the MTB proteins were successfully expressed in
soluble format using this system. Most of the purified proteins
had a concentration suitable for protein microarray fabrication
(0.1 to 5 mg of protein was purified from 12 ml cultures). To
further test the efficacy of the yeast expression system, we
independently expressed 184 membrane proteins randomly
selected from the 487 membrane proteins included on the
microarray (MTB H37Rv has a total of 567 membrane proteins)
and checked their expression by anti-GST western blotting.
Results show that 84.23% (155/184) were solubly expressed,
a slightly lower percentage than that of the 249 randomly
selected proteins (Data S1).
We next spotted the full set of purified recombinant proteins,
in duplicate, along with a set of controls (elution buffer, GST,
BSA, and histones), on a single glass slide and evaluated the
quality of the resulting array by probing with an anti-GST anti-
body (Figures 1D and S2A). The final protein set on the proteome
microarray, consisting of 3,829 of the 4,016 ORFs of the MTB
H37Rv proteome, was composed of 32% hypothetical proteins
(Figure S2B), 10% membrane proteins, and 5% secreted pro-
teins (Figure S2C), consistent with the known overall composi-
tion of the MTB proteome (Schubert et al., 2013) (proteins that
we were unable to clone or express, and thus are not present
on the current MTB proteome microarray, are listed in Table
S1). This high coverage and close similarity in composition
between our proteome microarray and that of the MTB prote-
ome indicates that it should be suitable for a variety of global
functional studies.
The distributions of foreground and background signal inten-
sity exhibited typical bell-shaped curves, and the curves for fore-
ground intensity (Figure S2D) and background intensity were
almost completely separate, indicating that the vast majority of
the printed spots on the microarray contained substantial levels
of recombinant protein. Signal intensity was not significantly
correlated with gene GC content, molecular weight (MW), or iso-
electric point (Figures S2E–S2G), indicating that these variableshors
Figure 1. Construction of the MTB Prote-
ome Microarray
(A) Protocol for high-throughput expression and
purification of M. tuberculosis proteins.
(B and C) Quantitation and quality determination
of purified M. tuberculosis proteins. Stars mark
bands that are of the expected size for the
given protein. (B) Protein quality was determined
using an anti-GST antibody. (C) Capillary elec-
trophoresis determination of protein quantity
and size.
(D) A total of 3,829 and 433 proteins from MTB
strains H37Rv and CDC1551, respectively, were
spotted in duplicate on polymer slides (Polymer-
Slide H, CapitalBio). The slides were probed with
an anti-GST antibody.
See also Figures S1 and S2 and Data S1 and S2.did not affect the success of protein purification. To estimate
the false-positive rate, we adopted a statistical model developed
by Wang et al. for DNA microarray analysis (Wang et al., 2003).
Given that the discordance rate of two replicated microarrays
in proteome microarray experiments can easily be kept under
10% (the discordance rates for the PknG and c-di-GMP
microarray experiments described below were 4.9% and
5.8%, respectively), the false-positive rate is (10%)2 /(1  2 3
10% + (10%)2) = 1.23%.
The above analyses indicate that the yeast system is suitable
for high-throughput expression and purification of MTB proteins.
This microarray represents the most comprehensive MTB pro-
teome microarray composed of individually purified proteins
reported to date. Since affinity purification of proteins is pro-
tein-friendly, it is likely that the proteins on the microarray, like
those on widely used human and yeast proteome microarrays
prepared using the same protocols (Jeong et al., 2012; Zhu
et al., 2001), are functionally active.
We demonstrate the broad utility of the MTB proteome micro-
array for functional studies in the experiments that follow by
using it in three typical applications: investigations of protein-
protein interactions and small-molecule-protein binding and
identification of serum biomarkers.Cell Reports 9, 2317–2329, DeGlobal Kinase-Protein Interactions
Protein serine/threonine kinases (PSTKs)
play important roles in antibiotic resis-
tance, host-pathogen interactions, and
the survival of MTB in macrophages
(Tiwari et al., 2009). MTB has 11 PSTKs,
indicating that Ser/Thr phosphorylation
is likely an important mechanism for
signal transduction in this organism (Pri-
sic et al., 2010). Of these, PknG is of
particular interest, as it is secreted into
the host cytosol (Walburger et al., 2004)
and plays a key role in infection (Sze´kely
et al., 2008). It may thus have significant
potential as a drug target (Scherr et al.,
2007); however, its regulation and themechanism by which it regulates the function of other proteins
is still poorly understood.
To date, the only MTB protein known to bind to PknG is GarA
(Rv1827), a key component of the glutamate metabolic pathway
(O’Hare et al., 2008). To identify additional PknG-interacting
proteins, we purified N-terminal V5-tagged PknG and used it to
probe the MTB proteome microarray (Figure 2). Using the strin-
gent criteria described in Experimental Procedures, we identified
59 candidate PknG-interacting proteins (Table S2), 20 of which
are known to be secreted (Ma˚len et al., 2007). The six proteins
with the strongest interactions are shown in Figure 2B.
To understand the biological relevance of the 59 candidate
PknG interactors (Table S2), we examined their enrichment in
specific protein classes using PANTHER (Mi et al., 2013). The
PknG interactors classified into 14 protein classes (Figure 2C),
the top three of which were hydrolases (17.8%), transferases
(17.8%), and oxidoreductases (13.3%). While previous studies
have largely focused on the role of PknG in glutamate and gluta-
mine metabolism (O’Hare et al., 2008), our results suggest that
PknG’s activity and substrate specificity may be regulated by a
variety of proteins involved in widespread biological processes.
Gene ontology (GO) analysis based on DAVID (Huang et al.,
2009) showed that the 59 candidate PknG interactors arecember 24, 2014 ª2014 The Authors 2319
Figure 2. Identification of PknG Interactors
and Interaction Kinetics
(A) Schematic of the procedure for detection of
binding events. A V5-specific monoclonal antibody
was applied to the microarray followed by incuba-
tion with a Cy5-labeled secondary antibody. GarA
(Rv1827) and BSA were used as positive and
negative controls, respectively.
(B) Representative PknG-interacting proteins. Cy5
signals were measured at 635 nm. Two replicate
results are shown. +, in the presence of PknG; , in
the absence of PknG.
(C) PANTHER classification of PknG interactors.
(D) Bilayer interferometry data for the binding of
PknG to selected proteins identified as interactors
on the MTB proteome microarray and their inter-
action kinetics. PknG was immobilized on strepta-
vidin-coated biosensors and exposed to binding
partners in SD buffer. Binding was measured by
coincident changes in the interference pattern. Re-
sults presented are representative of at least three
experiments.
(E) Y2H validation of representative PknG-protein
interactions. S. cerevisiae strain AH109 competent
cells were transformed with the plasmid combina-
tions indicated (bait plus prey) to assay for in-
teractions between PknG and the selected proteins.
PknG was used as the bait protein and Rv0334
(RmlA), Rv1525 (Wbbl2), and Rv1935 (EchA13)
as prey. Rv1827 (GarA) and an empty pGADT7
were included as positive and negative controls,
respectively.
(F) PknG phosphorylates RmlA and Wbbl2. PknG
was incubated with RmlA or Wbbl2 for 1 hr at 30C.
RmlA/Wbbl2 phosphorylation was subsequently
detected by western blotting with a phospho-
serine/threonine antibody.
(G) RmlA activity is inhibited by PknG. An RmlA
activity assay was performed using D-Glc-1-P
and dTTP as substrates. The major product
of this reaction, dTDP-d-Glc, was measured by
ultraperformance liquid chromatography mass
spectrometry.
See also Data S3.
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significantly enriched in transferase activity, with 10 proteins
being annotated as transferases (p = 0.014), and are slightly en-
riched in membrane proteins (Table S2).
Putative PknG-protein interactions were validated by Bio-
Layer Interferometry (BLI) (Abdiche et al., 2009) and yeast-two-
hybrid analysis, using Rv1827 (GarA), a known PknG binder, as
a positive control. Sufficient quantities of protein for BLI analysis
were obtained for 47 of the 59 putative interactors, and 72.3%
(34/47) of these showed strong interactions with PknG (Data
S3), indicating that these interactions are of relatively high affin-
ity. PknG and BSA showed no interactions under the same con-
ditions. For example, the equilibrium dissociation constants (KD)
for the interactions between PknG and Rv1827 (GarA), Rv0334
(RmlA), Rv1525 (Wbbl2), and Rv1935c (EchA13) were deter-
mined to be 83.8 nM, 80.6 nM, 38.1 nM, and 108 nM, respec-
tively (Figure 2D). A few representative putative PknG interactors
were selected for further validation by yeast two-hybrid analysis.
Results confirmed that RmlA and EchA13 are genuine interac-
tions (Figure 2E). Together, these results strongly suggest that
most of the PknG interactors are authentic and that PknG may
thus either have broad substrate specificity or be regulated by
a variety of other proteins.
Interestingly, we found that PknG interacts with two key com-
ponents of the rhamnose pathway that are essential for the
growth of MTB: (1) RmlA (Rv0334), a-D-Glc-1-P-thymidylyltrans-
ferase, which catalyzes the formation of dTDP-Rha from thymi-
dine triphosphate and glucose-1-phosphate, the first of four
steps in the synthesis of L-rhamnose, and (2) Wbbl2 (Rv1525),
a predicted rhamnosyl transferase possibly involved in cell wall
arabinogalactan linker formation that inserts a rhamnose residue
into the cell wall (Griffin et al., 2011). Rhamnose plays an essen-
tial structural role in the linker disaccharide that joins the pepti-
doglycan and arabinogalactan components of themycobacterial
cell wall (Brennan, 2003). As such, the rhamnose synthesis
pathway has been viewed as a potential target for the design
of inhibitors of bacterial growth (Grzegorzewicz et al., 2008).
Having verified the interactions between PknG and RmlA and
Wbbl2, we performed in vitro kinase assays (Prisic et al., 2010)
to test whether PknG phosphorylates RmlA and Wbbl2. Results
demonstrate clearly that both RmlA and Wbbl2 are phosphory-
lated by PknG (Figure 2F). We next measured the activity of
RmlA when PknG and ATP were included in the reaction directly
to test whether the interaction of RmlA with PknG alters its activ-
ity, (Figure 2G). Results indicated that PknG sharply inhibits the
activity of RmlA in vitro, decreasing the dTDP-d-Glc reaction
product peak area from 12.14 to 4.06 (mV*min), suggesting
that RmlA activity may be regulated by its phosphorylation by
PknG. Further experimental work is required to investigate the
ultimate impact of the RmlA and PknG interaction on rhamnose
and cell wall biosynthesis.
Global Profiling of c-di-GMP-Protein Interactions
c-di-GMP is a ubiquitous second messenger in bacteria that
regulates a wide range of cellular processes such as biofilm for-
mation, virulence, motility, and differentiation (Hengge, 2009). Its
functional diversity can be attributed to its diverse upstream
ligands and downstream effectors (Ro¨mling et al., 2013).
Although genomic, biochemical, and gene expression profilingCell Restudies have clearly demonstrated that c-di-GMP signaling
is active and may play important roles in M. tuberculosis (Li
and He, 2012), our understanding of downstream effectors
in M. tuberculosis, i.e., the proteins that c-di-GMP binds
to, is very limited. The physiological roles of c-di-GMP in
M. tuberculosis are thus still elusive.
To identify c-di-GMP-interacting proteins, we probed theMTB
proteome microarray with a biotinylated c-di-GMP, then incu-
bated it with Cy3-labeled streptavidin to detect binding events
(Figure 3A). The top six of the 30 potential c-di-GMP-interacting
proteins identified are shown in Figure 3B (Table S3).
Classification of these 30 candidate c-di-GMP binders using
PANTHER (Table S3) showed that they are represented in 12
protein classes (Figure 3C), the top four of which are transferases
(28.6%), hydrolases (21.4%), transporters (14.3%), and kinases
(14.3%). These data suggest that c-di-GMP may bind to a wide
range of proteins in diverse protein classes, consistent with re-
ports that c-di-GMP signaling is involved in the regulation of
many biological processes in other bacterial species (Ro¨mling
et al., 2013). GO analysis based on DAVID (Huang et al., 2009)
showed that the 30 c-di-GMP binders are significantly enriched
in various functions including ABC-2 type transporters (p =
0.002), biphenyl-2,3-diol 1,2-dioxygenase activity (p = 0.006),
and N-terminal protein amino acid acetylation (p = 0.006;
Table S3).
We next examined the 30 candidate c-di-GMP binding pro-
teins for consensus sequences that may represent important
binding sites, performing a Dilimot motif search for enriched mo-
tifs (Neduva et al., 2005) on the primary amino acid sequences.
The most significant motif identified, AxxxxAxV (p = 1.35 3
109), was present in 12 of the 30 binders. The well-known
GGDEF, EAL, and PilZ domains, commonly found in c-di-GMP
biosynthetic enzymes and some other binding proteins (Navarro
et al., 2009), were not found in any of the 30 candidate c-di-GMP
binding proteins identified here. Indeed, none of the H37Rv pro-
teins present in the Pfam database (Finn et al., 2010) carry PilZ
domains, only one protein (Rv1354c) carries a GGDEF domain,
and two proteins (Rv1354c and Rv1357c) carry EAL domains.
In view of the limited research to date on the role of c-di-GMP
in MTB, it is not surprising that we have identified motifs among
the 30 binders. Further detailed experimental investigation is
necessary to understand the functional or regulatory role these
structural motifs may play.
To validate these candidate c-di-GMP-protein interactions,
we purified seven randomly selected proteins and incubated
them with biotinylated c-di-GMP before performing western
blotting with streptavidin to detect interactions (Figure 3D).
Results clearly showed that c-di-GMP strongly interacts with
all seven proteins but bound relatively weakly to the positive con-
trol Rv0767c, a known c-di-GMP binder (Li and He, 2012), and
not at all to BSA.
BLI analysis of the interactions and kinetic parameters of puta-
tive c-di-GMP interactors Rv1525 (Wbbl2), Rv3756c (ProZ), and
Rv1478 showed they had strong interactions with c-di-GMP and
that there was no interaction between c-di-GMP and BSA under
the same conditions. The equilibrium dissociation constants (KD)
for the interactions between c-di-GMP and Rv1525, Rv3756c,
and Rv1478 were 16.9 nM, 102 nM, and 138 nM, respectivelyports 9, 2317–2329, December 24, 2014 ª2014 The Authors 2321
Figure 3. Identification of c-di-GMP Interactors and Interaction Kinetics
(A) Schematic of the procedure for detecting binding events. After probing the MTB proteome microarray with a biotinylated c-di-GMP, binding events were
detected with Cy3-labeled streptavidin.
(B) Representative c-di-GMP-interacting proteins. Cy3 signals were measured at 532 nm. Two replicate results are shown. +, in the presence of biotinylated c-di-
GMP; , in the presence of biotin alone.
(C) PANTHER classification of c-di-GMP interactors.
(legend continued on next page)
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(Figure 3E), indicating, as expected, that these interactions are of
relatively high affinity. The positive control, Rv0767c, also had a
significant interaction with c-di-GMP, with a KD of 2.36 mM.
As the c-di-GMP-protein interactions validated here were
selected at random, it seems reasonable to expect that the inter-
actions of c-di-GMP with most of the proteins in Table S3 are
authentic. Thus, as in other bacterial species, c-di-GMP appears
to have a broad regulatory role in MTB.
Interestingly, like PknG, c-di-GMP also bound to Wbbl2,
a predicted rhamnose transferase in the rhamnose synthesis
pathway, as mentioned above. Further functional studies are
needed to test whether c-di-GMP binding alters the activity of
Wbbl2, thus affecting MTB cell wall synthesis.
Serum Biomarker Identification
Additional biomarkers for the diagnosis of TB and monitoring
of treatment are urgently needed to supplement the three well
known T cell antigens, ESAT-6, CFP-10, and Ag85, which are
currently used in T cell based assays such as ELISPOT (Hill
et al., 2007) but still lack sufficient diagnostic power to reliably
distinguish patients with active disease from healthy individuals
or provide treatment monitoring (Sester et al., 2011). B cell
antigens, such as those used in the diagnosis of Hepatitis B
(Jaroszewicz et al., 2010), can be easily applied via simple
serum-based ELISA assays or Colloidal gold test strips and
could potentially be used in routine TB diagnosis and treatment
monitoring.
Here, we used theMTB proteomemicroarray to identify serum
biomarkers for assessing therapy outcome, by comparing anti-
bodies present in sera from 189 TB patients with active disease
sampled before the onset of treatment with those from 150
‘recovered’ TB patients; individuals who were smear-positive
before treatment and became smear-negative after completing
six months of antibiotic treatment (Figure 4). There was no signif-
icant difference in the distribution of age and sex between the
two groups (Figure 4B). Samples were divided into an initial
training set (21 from the ‘‘patient’’ and 20 from the ‘‘recovered’’
groups) that was screened to identify disease-state-specific
protein antigens (data were analyzed using the Bioconductor
package in R 3.0.) and two test sets (64 and 104 samples from
the ‘‘patient’’ and 43 and 87 samples from the ‘‘recovered’’
groups in set 1 and set 2, respectively) that were used to validate
disease-state-specific antigens identified using the training set.
Sample sizes in the training and test sets were optimized to
maximize the likelihood of detecting all reactive proteins bearing
in mind the total number of samples available (339) and the5%
margin of error (0.95 confidence level) associated with this
population size (Data S4).
Disease-state-specific antigens showed hierarchical clus-
tering and were able to provide discrimination between the TB
patient and recovered groups in the training set (Figure 4C).(D) Streptavidin blotting of selected c-di-GMP interactors. Purified proteins were c
SDS-PAGE, proteins were transferred to a polyvinylidene fluoride membrane tha
GMP binder, and BSA were included as positive and negative controls, respecti
(E) BLI data for the binding of c-di-GMP to selected binding partners identified o
immobilized on streptavidin-coated biosensors and exposed to binding partner
pattern. Results presented are representative of at least three experiments.
Cell ReThe serum antibodies against 13 MTB proteins were at signifi-
cantly higher levels in TB patients than that in the recovered
group, while that for GroEL (Rv0440) was significantly lower
(p < 0.05; Table 1). Both rounds of validation confirmed that
this panel of candidate biomarkers likely has potential for moni-
toring therapy outcome (Figure 4D). The diagnostic accuracy of
the 14 candidate biomarkers identified here (Table 1; Data S4),
assessed by receiver operating characteristic (ROC) curves us-
ing the Daim package in R 3.0.1, reached 78.4%, with a sensi-
tivity of 80.2% and specificity of 79.0% (Figure 4E), indicating
that this set of biomarkers has good potential as an index for
monitoring treatment outcome.
DISCUSSION
Systems biology approaches are beginning to unlock many
aspects of the basic biology of MTB and its host-interactions,
which have hitherto been bottlenecks in the development of
more effective therapeutic approaches for the treatment of
tuberculosis (McFadden et al., 2013). However, we do not yet
have a global picture of intracellular and MTB-host interactions
at the protein level due to a lack of suitable proteome-scale tools.
The proteome microarray described here for MTB contains
affinity-purified proteins and provides a convenient and versatile
platform for proteome-scale functional studies. The MTB
ORFome library constructed here (with >95% coverage of the
MTB proteome) will also facilitate functional studies, as it
provides a solution for readily expressing and purifyingMTB pro-
teins in soluble form. We have demonstrated the broad utility of
the microarray by investigating global protein interactions with
PknG, a Ser/Thr kinase and potential drug target, and c-di-
GMP, a ubiquitous prokaryotic second messenger, identifying
59 candidate PknG-interacting proteins and 30 candidate c-di-
GMP binders. Of particular interest, and demonstrating the po-
wer of unbiased global studies to generate unexpected and
insightful results, these two independent investigations unex-
pectedly intersected, both bringing regulation of the rhamnose
biosynthesis pathway enzymes RmlA and Wbbl2 into the spot-
light. In addition, we identified 14 serum biomarkers that have
potential as an index for monitoring treatment outcome; used
together, they can discriminate between patients with active
disease and those who have recovered from TB.
Our goal was to design a convenient experimental platform to
expedite systems-level functional studies of this slow-growing
and experimentally intransigent pathogen. To ensure the micro-
array was of high quality (high coverage of the MTB proteome
with proteins of high purity), good reproducibility, and broad
utility, we first constructed a complete MTB ORFome library,
then expressed proteins using a yeast system. Proteins were af-
finity-purified via GST tags and spotted onto glass slides. This
strategy maximizes protein purity and increases the likelihoodoincubated with 10 mMbiotin-c-di-GMP. After bring electrophoresized on 10%
t was incubated with an IRDye 800 CW streptavidin. Rv0767c, a known c-di-
vely.
n the MTB proteome microarray and their interaction kinetics. c-di-GMP was
s in buffer. Binding was measured by coincident changes in the interference
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Figure 4. Identification of Serum Biomarkers for Recovery from TB
(A) Schematic of the experimental procedure for determining differential expression. Microarrays were probed with serum samples from patients with active TB
disease or individuals who had recovered from TB and bound serum antibodies were detected by incubation with cy3-anti-immunoglobulin G.
(B) Characteristics of study population.
(C) Differentially expressed proteins showed hierarchical clustering, successfully discriminating between the TB patient and recovered groups.
(D) Violin plots of proteins expressed at significantly higher levels in TB patients than in recovered individuals. P, serum samples from TB patients; R, serum
samples from recovered individuals. The median (white horizontal line within central black box), interquartile range (black box), and minimum and maximum
values (black whiskers) are indicated. The yellow shaded area represents a kernel density plot. The significance of comparisons was tested using the
Mann-Whitney U test (two tailed).
(E) Receiver operating characteristic curve.
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Table 1. Candidate Serum Biomarkers Identified with the MTB
Proteome Microarray
Rv Number Annotation
1 Rv0324a sulfurtransferase
2 Rv0537cb probable integral membrane protein
3 Rv1685c transcriptional regulator, TetR family
4 Rv2072cc precorrin-6Y C(5,15)-methyltransferase
5 Rv3899cd uncharacterized protein
6 Rv1100a conserved protein
7 Rv1865c oxidoreductase, short-chain dehydrogenase/
reductase family
8 Rv3881ca,d,e,f ESX-1 secretion-associated protein EspB
9 MT0124 putative uncharacterized protein
10 Rv2884 probable transcriptional regulator protein
11 MT3959 putative uncharacterized protein
12 Rv2564b uncharacterized ABC transporter ATP-binding
protein
13 Rv1654a acetylglutamate kinase
14 Rv0440a,f 60 kDa chaperonin 2
Annotations are based on the Sanger Institute database (http://
tuberculist.epfl.ch/). See also Data S4.
aSecreted protein identified by Albrethsen et al. (Albrethsen et al., 2013).
bAnnotated as a membrane protein.
cLocated in the RD12 region of the genome (Behr et al., 1999).
dSecreted protein identified by Ma˚len et al. (Ma˚len et al., 2007).
eIdentified previously as a serum biomarker (Kunnath-Velayudhan et al.,
2010).
fConstituent of PPD (Prasad et al., 2013).of correct protein folding, making the microarray suitable for
functional studies. Although the current MTB proteome micro-
array already covers most of the MTB H37Rv proteome, our
aim is to provide a microarray with 100% coverage. We are
currently working to overcome problems encountered with the
expression of the remaining 228 H37Rv proteins (Table S2),
including several proteins of particular interest, i.e., GyrB, IniA,
PknG, and KatG. As the absence of these proteins may hinder
some applications of the proteome microarray, especially in
studies related to these proteins, we will add these proteins
when we update the microarray. While significant time, cost,
and effort have been invested in the construction of this platform,
the resulting microarrays are easy to use, versatile, and give
reliable and reproducible results, without the need associated
with other microarray platforms for performing in vitro translation
experiments before use (Kunnath-Velayudhan et al., 2010),
with their concomitant challenges in terms of protein purity and
reproducibility.
Our screens for PknG and c-di-GMP binding proteins identi-
fied a significant number of binders (59 for PknG and 30 for
c-di-GMP; Tables S2 and S3). BLI screening (Figures 2 and 3;
Data S3) validated 72% of the PknG interactions, confirming
the reliability of the microarray. Based on this rate of validation,
if we assume that all the validated interactors are functionally
active for protein-protein interactions, we estimate that the array
can potentially detect 65% (0.9 3 0.72 3 100) of all possible
interactions of the proteins on the microarray. BioinformaticCell Reanalyses of the binders suggest the involvement of PknG
and c-di-GMP in a broader range of biological processes than
previously appreciated (Tables S2 and S3). PknG is known to
be secreted and plays a role in host-pathogen interactions;
Walburger et al. showed that secretion of PknG enhancesmyco-
bacterial survival within macrophages by inhibiting phagosome-
lysosome fusion (Walburger et al., 2004). It is therefore of interest
that 20 of the interactors identified here are also reported to be
secreted (Albrethsen et al., 2013;Ma˚len et al., 2007). The remain-
ing binding partners are cytosolic and thus indicate that PknG
may also play important intracellular regulatory roles. Further
detailed functional studies are required to determine the biolog-
ical significance of the interactions identified here.
Having a comprehensive picture of the proteins that are regu-
lated by c-di-GMP or that regulate c-di-GMP intracellular levels
should greatly expand our understanding of MTB pathophysi-
ology. In other bacterial species, c-di-GMP levels are known to
regulate a variety of biological functions. The high level of confi-
dence associated with the c-di-GMP binding proteins identified
here opens up the possibility of exploring these functions in
MTB. In addition, c-di-GMP is also known as a regulator of im-
mune responses to pathogen infection (Burdette et al., 2011).
Investigation of the regulation of c-di-GMP itself, especially its
levels and polarization in the cell, will likely provide important
insights into host immune responses.
Unexpectedly, our results showed that both PknG and c-di-
GMP interact with enzymes of the rhamnose synthesis pathway,
a pathway that is crucial in cell wall synthesis. As drugs that
inhibit cell wall biosynthesis are among the most highly effective
antibiotics in use against TB, these findings may point toward
additional strategies for drug design. Rhamnose is a glycan not
found in humans and plays a key structural role in the mycobac-
terial cell wall (Brennan, 2003). Both the rhamnose biosynthesis
pathway enzymes RmlA (interacts with PknG; Figure 2) and
Wbbl2 (interacts with both PknG and c-di-GMP; Figures 2
and 3) are essential for the survival of M. tuberculosis (Griffin
et al., 2011) and thus may be attractive drug targets. In addition,
Wbbl2 is specific to the mycobacteria. Our investigation pro-
vides insight on the rhamnose pathway, showing that both
PknG and c-di-GMP are likely involved in its regulation, suggest-
ing two further avenues of approach for developing drugs that
will inhibit cell wall synthesis.
Early proteomic studies onMTB have largely been descriptive,
yielding information on protein abundance, localization, and
differential expression under various conditions (Mehaffy et al.,
2012). As the fieldmoves away from a focus on simply cataloging
proteins to unraveling their cellular and pathophysiological
functions, two recent studies that address the lack of accurate
and specific antigen markers for active TB disease using high-
throughput approaches (Kunnath-Velayudhan et al., 2010; Liu
et al., 2014) deserve particular comment and comparison with
the approach taken here. Kunnath-Velayudhan et al. developed
an in vitro transcription and translation-based MTB proteome
microarray containing 3,988 unpurified proteins from the
H37Rv strain and probed it with human serum samples, identi-
fying 494 antigenic proteins. While this microarray has led to
significant progress in defining the MTB immunoproteome
(Kunnath-Velayudhan and Porcelli, 2013), the low purity of theports 9, 2317–2329, December 24, 2014 ª2014 The Authors 2325
proteins on the microarray limits its use in both analytical
and functional applications. Recognizing this limitation, Liu
et al. chose a different strategy, successfully performing high-
throughput cloning, expression, and purification of 1,250 MTB
proteins (Liu et al., 2014). Despite the restricted coverage of
the proteome, subsequent screening using semiquantitative
western blotting and ELISPOT assays identified 29 antigenic
proteins involved in humoral immune reactions and 34 in cellular
immune reactions. The MTB proteome microarray described
here, with its affinity-purified proteins, high-coverage of the
proteome, and convenient and versatile experimental platform,
offers an alternative platform that can be used for broader func-
tional and analytical studies aswell as the identification of protein
antigens in serum samples.
Studies on biomarkers, such as those described above, have
generally focused on identifying markers that can distinguish
healthy individuals from patients with active TB disease. Here,
we turned our attention to identifying biomarkers for monitoring
treatment outcome. The length of anti-TB therapy (6–8 months
for drug-sensitive TB and 2 years for drug-resistant TB) has
negative implications for patient adherence, making clinical
management of TB problematic (Lienhardt et al., 2012). As a
shortened course of antibiotics may be sufficient for individuals
responding early to treatment (Yew et al., 2011), early classifica-
tion of TB patients into risk groups requiring different lengths of
treatment is desirable to improve adherence and thus treatment
outcome. Inexpensive, reliable, and rapid tests such as simple
blood tests using serum biomarkers are needed to replace
sputum microscopy, the current gold standard for monitoring
the outcome of chemotherapy, because it lacks sensitivity and
a substantial proportion of baseline sputum samples from new
TB patients test negative (Steingart et al., 2006). The 14 bio-
markers identified here (Table 1; Data S4) had a diagnostic accu-
racy of 78.4%, sensitivity of 80.2%, and specificity of 79.0%
(Figure 4E), indicating that together they should be an effective
index for monitoring treatment outcome.
Our proteome microarray has many potential applications.
First, used to identify human proteins involved in host-pathogen
interactions, it could facilitate identification of the host processes
and interactions that are key in determining whether MTB
infection leads to development of active disease, asymptomatic
latent infection, or total clearance of bacteria. Second, it pro-
vides a versatile platform for investigating many aspects of the
basic biology of MTB at the systems level, including global
protein interactions with DNA, RNA, lipids, and global studies
of posttranslational modifications, such as the profiling of kinase
substrates demonstrated here. As such, this microarray repre-
sents a significant advance over traditional methodologies.
Third, it is a powerful platform for the direct global identification
of drug-targeted proteins, both for new drug candidates and
for compounds that are effective but whosemechanism is poorly
understood. The microarray could thus greatly accelerate mode
of action studies for TB drugs/compounds. Investigations utiliz-
ing treatment monitoring biomarkers could also play a key role
in the validation of drug candidates, accelerating drug develop-
ment by reducing the length of clinical trials. In addition, investi-
gations of the interactions between small molecules, their
targets, and the system as a whole using this platform could2326 Cell Reports 9, 2317–2329, December 24, 2014 ª2014 The Autlead to much-needed strategies for overriding the propensity
of MTB to develop drug resistance. Fourthly, the proteome
microarray could be used to identify potential biomarkers and
immunogens and to expand our understanding of basic TB
immunology. Examining serological differences among different
groups of people, such as healthy individuals, those with latent
TB, patients with active disease, and those recovered from TB,
should lead to identification of useful diagnostic and therapeutic
biomarkers.
Results reported here demonstrate that a systems-level
approach utilizing our MTB proteome microarray can rapidly
provide insightful proteome-wide information that opens up
further avenues of research on the basic biology of MTB. This
versatile proteome microarray with its many applications may
greatly expedite research on this experimentally intransigent
pathogen, ultimately leading to much-needed more effective
therapeutic strategies and interventions for the treatment of TB.
EXPERIMENTAL PROCEDURES
MTB Proteome Microarray Construction
Cloning of MTB ORFs and protein purification was performed using pub-
lished methods (Newman et al., 2013; Zhu et al., 2001). The entry clone
collection, consisting of 3,404 H37Rv and 437 CDC1551 fully sequenced
ORF clones, was a kind gift from the PFGRC (Rockville, MD). We designed
primers for full-length Gateway-compatible cloning of 794 H37Rv ORFs
that were either missing or had frameshift mutations/were truncated in the
PFGRC collection using Primer Premier 5.0 from PREMIER Biosoft, following
the same criteria used in the construction of the PFGRC collection. Primers
were synthesized by Sangon Biotechnology. PCR amplification was carried
out using a Phusion High-Fidelity PCR Kit (New England Biolabs), and the
purity and identity of the PCR products was verified by gel electrophoresis.
Verified PCR products were purified using PCR cleaning kit DP204 (Tiangen
Biotech) and then subjected to the Gateway BP reaction using donor vector
pDONR221 and Gateway BP mix (Life Technologies) according to the man-
ufacturer’s instructions. All sequence-verified entry clones were subjected to
the Gateway LR reaction using pEGH-A (Lin et al., 2009) as the destination
vector, then transformed into competent cells of S. cerevisiae strain Y258.
Approximately 4,000 proteins, representing most of the proteome of MTB
strain H37Rv, were then expressed and affinity-purified using GST tags
and glutathione agarose beads using the protocol described by Zhu et al.
(Zhu et al., 2001). After elution and quality control by western blotting with
an anti-GST antibody and capillary electrophoresis, each protein was spotted
twice on polymer slides (Polymer-Slide H; CapitalBio) using a SmartArrayer
48 microarrayer (CapitalBio). The resulting microarrays were stored at
80C prior to use.
Global Profiling of PknG-Protein Interactions
MTB proteome microarrays were blocked for 1 hr at room temperature with
shaking in blocking buffer (1xPBS, 3% BSA, 0.1% Tween 20 [pH 7.4]). After
blocking, 200 ml purified V5-tagged PknG at a final concentration of 0.05 mg/
ml in blocking buffer was loaded onto the microarray, which was then covered
using a Liftslip (Grace Bio-Labs) during incubation. Arrays were incubated in a
humidified chamber for 1 hr at 4Cwithout shaking, thenwashed three times in
Tris-buffered saline solution containing 0.1% Tween 20 detergent (TBST).
Arrays were probed with 1 ml mouse anti-V5 antibody (1 mg/ml in blocking
buffer; Sigma-Aldrich) and incubated in a humidified chamber for 1 hr at
room temperature. After washing three times in TBST, arrays were probed
with 1 ml cy5-donkey-anti-mouse antibody (1 mg/ml in blocking buffer; Jack-
son ImmunoResearch Laboratories) and incubated in a humidified chamber
for 1 hr at room temperature. After washing three times in TBST, arrays were
dried in a SlideWasher (CapitalBio) and then scanned with a GenePix 4200A
microarray scanner (Molecular Devices). Data were analyzed with GenePix
Pro 6.0 (Molecular Devices).hors
Global Profiling of c-di-GMP-Protein Interactions
MTB proteome microarrays were blocked for 1 hr at room temperature with
shaking in blocking buffer (3% BSA, 1xTBST, and 0.1% Tween 20 [pH 7.4]).
The 1 mM biotin-c-di-GMP (BioLog Life Science Institute) and 1 mM biotin
(Sigma-Aldrich) solutions were prepared in 3 ml PBS and added respectively
to deep-well plates containing a blocked microarray, ensuring that the micro-
array was covered during probing. After incubating overnight at 4C with
shaking, arrays were washed three times with shaking in 1xTBST and then
probed with 3 ml Cy3-strepavadin (1 mg/mL in 1xTBST buffer; Sigma-Aldrich)
for 1 hr at room temperature with shaking. After washing three times in 1xTBST
and once in ddH2O, arrays were dried in a SlideWash (Capital Bio) and then
scanned in a GenePix 4200A slider scanner (Molecular Devices). Data were
analyzed with GenePix Pro 6.0 (Molecular Devices).
ProteinMicroarray Data Analysis of PknG and c-di-GMP Interactions
Data were extracted from the microarray images by GenePix Pro 6.0 (Molec-
ular Devices) and then processed using an R package developed in our lab
(http://www.protein--microarray.com). To generate candidate lists, the signal
to noise ratio (SNR) was defined as F635 median/B635 median. The SNR of
each protein was averaged for the two duplicated spots on each microarray
incubated with (SNR+) or without (SNR) PknG/c-di-GMP. Proteins with
positive signals were identified on each array based on the assumption that
background values across the array followed a normal distribution. The
median SNR of all proteins was used to estimate the mean of the normal dis-
tribution, and the median absolute deviation (MAD) was used to estimate the
SD of the normal distribution. Proteins with p values < 0.01 were considered
as positive interactors. To identify which proteins had significantly higher
SNRs in the microarray incubated with PknG/c-di-GMP than in the control
microarray, calling score was defined as SNR+/SNR and calculated for all
the proteins, assuming that the calling scores of proteins whose signal was
not significantly different between the control microarray and the microarray
incubated with PknG/c-di-GMP followed a normal distribution. Cutoff values
were set as calling score >2 and SNR >3 for PknG-interacting proteins and
Calling score >3 and SNR >3 for c-di-GMP-interacting proteins.
Candidate PknG and c-di-GMP binding proteins were classified using the
PANTHER classification system (Mi et al., 2013) with default settings. Gene
symbols were used as input.
Candidate c-di-GMP binding proteins were examined for motif enrichment
using Dilimot, a linear motif-predicting tool (Neduva et al., 2005). Default set-
tings were used, except that the maximum length for motifs was set at 8.
Serum Biomarker Identification
Serum samples from TB patients and recovered individuals who met the eligi-
bility criteria were collected at Guangdong Center for Tuberculosis Control
between 2011 and 2012. The study was approved by the Ethics Committee
of the Guangdong Center for Tuberculosis Control and informed consent
was obtained from each individual participating in the study before sampling.
Samples were grouped according to the disease status of the donor into two
phases of MTB infection, i.e., patients diagnosed with TB before treatment for
active disease who were smear positive, and recovered individuals who were
smear positive before treatment and became smear negative after successful
completion of antibiotic treatment.
Each serum sample (3 ml, diluted 1:100 in TBST) was overlaid on a protein
microarray and incubated at room temperature for 1 hr. After washing three
times with TBST, bound serum antibodies were detected by incubation for
1 hr at room temperature with Alexa Fluor 532 goat anti-human immunoglob-
ulin G (H+L) (Jackson ImmunoResearch Laboratories) diluted 1:1,000 in TBST.
After washing with TBST and drying in a SlideWasher (CapitalBio), arrays were
scanned in a GenePix 4200A (Molecular Devices). The median foreground and
background fluorescence intensity were obtained for each spot in the protein
microarrays using GenePix 6.0 (Molecular Devices). The raw intensity of each
spot was defined as the ratio of the foreground to the background median
intensity. To remove the negative effects of nonspecific binding and spatial
heterogeneity across the protein array, the background processing method
‘‘normexp’’ (Ritchie et al., 2007) was used for background correction. The Nor-
malizeBetweenArrays package (Bolstad et al., 2003) in ‘‘limma’’ was employed
for quantile normalization.Cell ReTwenty-one samples from the ‘‘patient’’ and 20 samples from the ‘‘recov-
ered’’ groups were used as an initial training set to identify differentially ex-
pressed proteins using the Bioconductor package in R 3.0. Normalized protein
expression values were transformed to log2 values, and all proteins on the
protein microarrays were ordered by their fold-change values. To validate
the differentially expressed proteins identified using the training set, the above
analysis was repeated on two test sets (64 and 104 samples from the ‘‘patient’’
and 43 and 87 samples from the ‘‘recovered’’ groups in set 1 and set 2, respec-
tively). Fisher’s test was employed to calculate p values for each protein
candidate, which were further adjusted for multiple testing using the Benjamini
and Hochberg method to control the false discovery rate. The p value cutoff
was set to 0.05. The ‘‘vioplot’’ and ‘‘Daim’’ packages in R 3.1.0 were used to
generate Violin plots and to calculate the sensitivity, specificity, and area under
the curve for the differentially expressed proteins.
Sample size was defined as ss = Z2p(1 p)/c2, where c is themargin of error
(also called the confidence interval) that can be tolerated, p is the percentage
of samples chosen, and Z is a constant that is dependent on the confidence
interval (e.g., Z = 1.96 for a 95% confidence interval).
Details of other experimental procedures are described in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, three tables, and four data sets and can be found with this article
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